Challenges for corporate ethics in marketing genetic tests

Journal of Business Ethics

Volumn 77, Issue 1, 2008, Pages 33-44

  Williams Jones, Bryn ^a   Ozdemir, Vural ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biotechnology; Business ethics; Commercialization; Corporate ethics; Disease susceptibility; Genetic testing; Intellectual property rights; Marketing; Pharmacogenomics; Truth in advertising

Indexed keywords

EID: 36549090089     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-006-9299-7     Document Type: Article

References (53)

1. Angell M. (2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It. Random House, New York
2. Belluck, P.: 1997, 'Everybody's Doing It: Paternity Testing for Fun and Profit', New York Times, August 3, p. 1, 4
3. Bowen D. J., K. M. Battuello, M. Raats (2005) Marketing Genetic Tests: Empowerment or Snake Oil? Health Education & Behavior 32(5), 676-685
4. British Medical Association: 2005, Population Screening and Genetic Testing: A Briefing on Current Programmes and Technologies (British Medical Association, London)
5. Burgess M. M. (1999) Marketing and Fear-Mongering: Is It Time for Commercialized Genetic Testing? In T. A. Caulfield, B. Williams-Jones (eds.), The Commercialization of Genetics Research: Ethical, Legal, and Policy Issues. Kluwer Academic/Plenum Publishers, New York, NY, pp 181-194
6. Caulfield T. (2005) Policy Conflicts: Gene Patents and Health Care in Canada. Community Genetics 8(4), 223-227
7. Caulfield, T. A., M. M. Burgess, B. Williams-Jones, with, M.-A. Baily, R. Chadwick, M. Cho, R. Deber, U. Fleising, C. M. Flood, J. Friedman, R. Lank, T. Owen and J. Sproule: 2001, 'Providing Genetic Testing through the Private Sector: A View from Canada', ISUMA: Canadian Journal of Policy Research 2(3), 72-81 (http://www.isuma.net/v02n03/caulfield/caulfield_e.pdf)
8. Center for Drug Evaluation and Research. March 22, 2005, 'Ndas Approved in Calendar Years 1990-2004 by Therapeutic Potentials and Chemical Type,' Food and Drug Administration, Department of Health and Human Services (http://www.fda.gov/cder/rdmt/pstable.htm) [accessed: May 4 2006]
9. Chadwick, R.: 2004, 'Nutrigenomics, Individualism and Public Health', Proceedings of the Nutrition Society 63(1), 161-166
10. Cho M. K., S. Illangasekare, M. A. Weaver, D. G. B. Leonard, J. F. Merz (2003) Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services, Journal of Molecular Diagnostics 5(1), 3-8
11. Codori, A.-M.: 1997, 'Psychological Opportunities and Hazards in Predictive Genetic Testing for Cancer Risk', Gastroenterology Clinics of North America 26(1), 19-39
12. Danzon P., A. Towse (2002) The Economics of Gene Therapy and of Pharmacogenetics, Value in Health 5(1), 5-13
13. Dhanda R. K. (2002) Guiding Icarus: Merging Bioethics with Corporate Interests. Wiley-Liss, New York
14. Dhanda, R. K.: 2004, 'Bioethics in Biotechnology: From Pain to Gain', Drug Development Research 63(3), 93-102
15. Eisenberg R. S. (2002) Will Pharmacogenomics Alter the Role of Patents in Drug Development? Pharmacogenomics 3(5), 571-574
16. Finegold D., C. M. Bensimon, A. S. Daar, M. Eaton, B. Godard, B. M. Knoppers, J. E. Mackie, P. A. Singer (2005) Bioindustry Ethics. Elsevier Academic Press, Burlington, MA
17. Fleising U. (2001) In Search of Genohype: A Content Analysis of Biotechnology Company Documents, New Genetics & Society 20(3), 239-254
18. Frank T. S., A. M. Deffenbaugh, J. E. Reid, M. Hulick, B. E. Ward, B. Lingenfelter, K. L. Gumpper, T. Scholl, S. V. Tavtigian, D. R. Pruss, G. C. Critchfield (2002) Clinical Characteristics of Individuals with Germline Mutations in BRCA1 and BRCA2: Analysis of 10,000 Individuals, Journal of Clinical Oncology 20(6), 1480-1490
19. GeneWatch UK: 2003, 'The Dangers of Genetic Testing Kits', The Guardian, January 19, (http://www.observer.guardian.co.uk/science/story/0,(1596),877583, 00.html) [accessed: May 4 2006]
20. Gillam L. (1999) Prenatal Diagnosis and Discrimination against the Disabled, Journal of Medical Ethics 25(2), 163-171
21. Gollust S. E., S. C. Hull, B. S. Wilfond (2002) Limitations of Direct-to-Consumer Advertising for Clinical Genetic Testing, Journal of the American Medical Association 288(14), 1762-1767
22. Gollust S. E., S. C. Hull, B. S. Wilfond (2003) Direct-to-Consumer Sales of Genetic Services on the Internet, Genetics in Medicine 5(4), 332-337
23. Hall M. A., S. S. Rich (2000) Laws Restricting Health Insurers' Use of Genetic Information: Impact on Genetic Discrimination, American Journal of Human Genetics 66(1), 293-307
24. Hellsten I. (2005) From Sequencing to Annotating: Extending the Metaphor of the Book of Life from Genetics to Genomics, New Genetics & Society 24(3), 283-297
25. Ho C., S. Banerjee, S. Mensinkai (2003). Molecular Diagnosis for Hereditary Cancer Predisposing Syndromes: Genetic Testing and Clinical Impact. Canadian Coordinating Office for Health Technology Assessment, Ottawa
26. Horrobin D. F. (2000) Innovation in the Pharmaceutical Industry, Journal of the Royal Society of Medicine 93(7), 341-345
27. Human Genetics Commission: 2003, 'Genes Direct: Ensuring the Effective Oversight of Genetic Tests Supplied Directly to the Public' (Human Genetics Commission, Department of Health, London), (http://www.hgc.gov.uk/UploadDocs/ Contents/Documents/Genes%20direct%20-%20FULL%20REPORT%20FINAL.pdf) [accessed: September 2, 2006]
28. Hutson S. P. (2003) Attitudes and Psychological Impact of Genetic Testing, Genetic Counseling, and Breast Cancer Risk Assessment among Women at Increased Risk, Oncology Nursing Forum 30(2), 241-246
29. Kaebnick G. E. (2004) The Natural Father: Genetic Paternity Testing, Marriage, and Fatherhood, Cambridge Quarterly of Healthcare Ethics 13, 49-60
30. Kalow, W.: 2006, 'Pharmacogenetics and Pharmacogenomics: Origin, Status, and the Hope for Personalized Medicine', The Pharmacogenomics Journal Jan 17 online publication
31. Lazarou J., B. H. Pomeranz, P. N. Corey (1998) Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies, Journal of the American Medical Association 279, 1200-1205
32. Lewis, C.: 2001, 'Home Diagnostic Tests: The Ultimate House Call?' FDA Consumer Magazine, pp. 18-22 (http://www.fda.gov/fdac/features/2001/601_home. html) [accessed: May 4 2006]
33. MacDonald C. (2002). Commercialization of Genetic Services: The Role of Genetic Counselors, Human Reproduction and Genetic Ethics 8(1), 1-3
34. MacDonald C., B. Williams-Jones (2002). Ethics and Genetics: Susceptibility Testing in the Workplace, Journal of Business Ethics 35(3), 235-241
35. Mykitiuk R. (2004). Caveat Emptor: Direct-to-Consumer Supply and Advertising of Genetic Testing, Clinical & Investigative Medicine 27(1), 23-32
36. Ozdemir, V. & B. Lerer: 2005, 'Pharmacogenomics and the Promise of Personalized Medicine,' in W. Kalow, U. A. Meyer and R. F. Tyndale (eds.), Pharmacogenomics, 2nd expanded edition ed (Taylor & Francis, New York), pp. 13-50
37. Ozdemir V., B. Williams-Jones, S. J. Glatt, M. T. Tsuang, J. B. Lohr, C. Reist (2006) Shifting Emphasis from Pharmacogenomics to Theragnostics, Nature Biotechnology 24(8), 942-946
38. Prospero L., M. Seminsky, J. Honeyford, B. Doan, E. Franssen, W. Meschino, P. Chart, E. Warner (2001) Psychosocial Issues Following a Positive Result of Genetic Testing for BRCA1 and BRCA2 Mutations: Findings from a Focus Group and a Needs-Assessment Survey, Canadian Medical Association Journal 164(7), 1005-1009
39. Ratcliff N. (2003) Marketing Genetics: The Need for Consumer Protection, Consumer Policy Review 13(1), 8-16
40. Reidenberg M. M. (2000) Are We Treating Health or Physical Appearance When We Prescribe Drugs for Obesity? Clinical Pharmacology and Therapeutics 67(3), 193-195
41. Service R. F. (2004) Surviving the Blockbuster Syndrome, Science 303(5665), 1796-1799
42. Sherrid, P.: 2001, 'Designer Drugs. What's Best for Patients Isn't Always What's Best for Profits', US News World Report 131, pp. 30-32
43. Shih H. A., F. J. Couch, K. L. Nathanson, M. A. Blackwood, T. R. Rebbeck, K. A. Armstrong, K. Calzone, J. Stopfer, S. Seal, M. R. Stratton, B. L. Weber (2002) BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic, Journal of Clinical Oncology 20(4), 994-999
44. Spear B. B., M. Heath-Chiozzi, J. Huff (2001). Clinical Application of Pharmacogenetics, Trends in Molecular Medicine 7(5), 201-204
45. Szabo C. I., M. C. King (1997) Population Genetics of BRCA1 and BRCA2, American Journal of Human Genetics 60(5), 1013-1020
46. Verbeure B., G. Matthijs, G. Van Overwalle (2005) Analysing DNA Patents in Relation with Diagnostic Genetic Testing, European Journal of Human Genetics 14(1), 26-33
47. Walsh T., S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, L. Foretova, P. Soucek, M.-C. King (2006) Spectrum of Mutations in BRCA1, BRCA2, Chek2, and Tp53 in Families at High Risk of Breast Cancer, Journal of the American Medical Association 295(12), 1379-1388
48. Williams-Jones B. (2003) Where There's a Web, There's a Way Commercial Genetic Testing and the Internet, Community Genetics 6(1), 46-57
49. Williams-Jones B. (2006) 'Be Ready against Cancer, Now': Direct-to-Consumer Advertising for Genetic Testing, New Genetics & Society 25(1), 89-107
50. Williams-Jones B., M. M. Burgess (2004) Social Contract Theory and Just Decision-Making: Lessons from Genetic Testing for the BRCA Mutations, Kennedy Institute of Ethics Journal 14(2), 115-142
51. Williams-Jones B., O. P. Corrigan (2003) Rhetoric and Hype: Where's The Ethics In Pharmacogenomics? American Journal of Pharmacogenomics 3(6), 375-383
52. Williams-Jones B., J. E. Graham (2003) Actor-Network Theory: A Tool to Support Ethical Analysis of Commercial Genetic Testing, New Genetics & Society 22(3), 271-296
53. Williams-Jones B., V. Ozdemir (2006). Enclosing the 'Knowledge Commons': Patenting Genes for Disease Risk and Drug Response at the University-Industry Interface. In C. Lenk, N. Hoppe, R. Andorno (eds.), Ethics and Law of Intellectual Property Current Problems in Politics, Science and Technology. Ashgate Publishing, London, pp. 177-208